-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 DOfk6I1ZJEteNzSYgSomesEHKkXoNtRStywCb40tN1/n2Cj3m9agY0hNy5U4FZOa
 p8f8STpsiHvUhew1vmFkow==

<SEC-DOCUMENT>0000950123-07-016999.txt : 20071226
<SEC-HEADER>0000950123-07-016999.hdr.sgml : 20071225
<ACCEPTANCE-DATETIME>20071226061134
ACCESSION NUMBER:		0000950123-07-016999
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20071221
FILED AS OF DATE:		20071226
DATE AS OF CHANGE:		20071226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KONINKLIJKE PHILIPS ELECTRONICS NV
		CENTRAL INDEX KEY:			0000313216
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTRONIC & OTHER ELECTRICAL EQUIPMENT (NO COMPUTER EQUIP) [3600]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-05146-01
		FILM NUMBER:		071324825

	BUSINESS ADDRESS:	
		STREET 1:		BREITNER CENTER
		STREET 2:		AMSTELPLEIN 2
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1096 BC
		BUSINESS PHONE:		31 20 59 77777

	MAIL ADDRESS:	
		STREET 1:		BREITNER CENTER
		STREET 2:		AMSTELPLEIN 2
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1096 BC

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPS ELECTRONICS N V
		DATE OF NAME CHANGE:	19930727

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPS NV
		DATE OF NAME CHANGE:	19910903
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>u54467e6vk.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e6vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>2007 &#151; 11</B>
</DIV>


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 6-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>REPORT OF FOREIGN ISSUER</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16 of the<BR>
Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>For the period commencing November&nbsp;27 through December&nbsp;21, 2007</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>KONINKLIJKE PHILIPS ELECTRONICS N.V.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Royal Philips Electronics</B></DIV>

<DIV align="center" style="font-size: 10pt">(Translation of registrant&#146;s name into English)</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>The Netherlands</B></DIV>

<DIV align="center" style="font-size: 10pt">(Jurisdiction of incorporation or organization)</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Breitner Center, Amstelplein 2, 1096 BC Amsterdam, The Netherlands</B></DIV>

<DIV align="center" style="font-size: 10pt">(Address of principal executive offices)</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form
20-F or Form 40-F.
</DIV>

<DIV align="center" style="font-size: 10pt">Form&nbsp;20-F&nbsp;<FONT face="Wingdings">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;40-F&nbsp;<FONT face="Wingdings">&#111;</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation&nbsp;S-T Rule101(b)(1):&nbsp;<FONT face="Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation&nbsp;S-T Rule101(b)(7):&nbsp;<FONT face="Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark whether the registrant by furnishing the information contained in this Form
is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the
Securities Exchange Act of 1934.
</DIV>

<DIV align="center" style="font-size: 10pt">Yes&nbsp;<FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT face="Wingdings">&#254;</FONT></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">Name and address of person authorized to receive notices<BR>
and communications from the Securities and Exchange Commission:</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">E.P. Coutinho<BR>
Koninklijke Philips Electronics N.V.<BR>
Amstelplein 2<BR>
1096 BC Amsterdam &#151; The Netherlands</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">







<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This report comprises a copy of the following press releases entitled:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;Philips updates markets on Consumer Lifestyle businesses&#148;, dated December&nbsp;06, 2007</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;Philips agrees to sell Set-Top Boxes and Connectivity Solutions businesses to Pace
Micro Technology of the UK&#148;, dated December&nbsp;19, 2007</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;Philips plans to repurchase an additional EUR 5&nbsp;billion worth of shares&#148;, dated
December&nbsp;19, 2007</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;U.S. antitrust conditions fulfilled for Philips&#146; acquisition of Genlyte&#148;, dated
December&nbsp;19, 2007</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;Philips to make public offer for all shares of US-based Respironics; a major step
forward for Philips Healthcare&#148;, dated December&nbsp;21, 2007</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf, by the undersigned, thereunto duly authorized at Amsterdam,
on the 21<SUP style="font-size: 85%; vertical-align: text-top">st</SUP> day of December&nbsp;2007.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>KONINKLIJKE PHILIPS ELECTRONICS N.V.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD nowrap colspan="3" align="left"><B>/s/ E.P. Coutinho</B>
&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR style="font-size: 1px">
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left">(General Secretary)&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Philips updates markets on Consumer Lifestyle businesses
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Thursday, December&nbsp;06, 2007

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Amsterdam, The Netherlands </B>&#151; In a meeting with investors and financial analysts today, Royal
Philips Electronics (AEX: PHI, NYSE: PHG) will provide an update on how its consumer lifestyle
businesses have and will continue to add value and sustainable growth to the company. Philips will
also elaborate on the formation of the new Philips Consumer Lifestyle sector as per January&nbsp;1, and
this new, integrated sector will help Philips achieve the targets set as part of its &#147;Vision 2010&#148;
strategic plan, which was communicated in September.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In separate presentations, the chief executives of both the Domestic Appliances &#038; Personal Care
(DAP)&nbsp;division as well as Consumer Electronics (CE)&nbsp;will highlight characteristics of the
portfolios and business models of their respective businesses, elaborate on past business
performance and detail why both businesses are in a strong position for the future. Rudy Provoost,
Chief Executive Officer of CE, will focus on explaining how the business&#146; asset-light strategy and
a focus on design and relevant innovation has allowed it to deliver consistent performance over the
past twelve quarters and will confirm that the division is on track to achieve an EBITA target of
around 3% for 2007. Mr.&nbsp;Provoost will also confirm that all businesses within CE continue to show
year-on-year improvement, except for Connected Displays, where margin pressure remains high,
particularly in North-America.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Andrea Ragnetti, Chief Executive Officer of DAP, will focus on the fundamentals of the strong
performance of its businesses and the key drivers of the sustainable growth in sales and margins
DAP has achieved. Mr.&nbsp;Ragnetti, who will become CEO of Philips Consumer Lifestyle sector effective
January&nbsp;1, will also elaborate on the strong prospects of Consumer Lifestyle going forward.
Combining key competencies of DAP and CE in one consumer lifestyle powerhouse and addressing a more
sizeable overall market than before by entering new value spaces, the Consumer Lifestyle sector is
excellently positioned to grow above market levels and deliver overall EBITA improvement. Mr.
Ragnetti will confirm that the formation of Consumer Lifestyle will lead to cost synergies of
around EUR 150&nbsp;million to EUR 200&nbsp;million a year by 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Presentations will begin at 10:00 AM (CET), and can also be followed via webcast. Please <u>click here</u>
to listen to this webcast. Please <u>click here</u> to go the Philips News Center &#147;Vision 2010&#148;
announcement page to see more details about the plan.
</DIV>

<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>Agenda, presentations and audiocast</B>
</DIV>


<DIV align="left" style="font-size: 12pt; margin-top: 6pt"><B>&#043; <U>Click here for the Analysts&#146; Day agenda, presentations and audiocast</U></B>
</DIV>

<DIV align="left" style="font-size: 12pt; margin-top: 6pt"><B>For further information, please contact:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Joon Knapen<BR>
Philips Corporate Communications<BR>
Tel: &#043;31 20 59 77477<BR>
Email: <U>joon.knapen@philips.com</U>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>About Royal Philips Electronics</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in
healthcare, lighting and consumer lifestyle, delivering products, services and solutions through
the brand promise of &#147;sense and simplicity&#148;. Headquartered in the Netherlands, Philips employs
approximately 128,100 employees in more than 60 countries worldwide. With sales of EUR 27&nbsp;billion
in 2006, the company is a market leader in medical diagnostic imaging and patient monitoring
systems, energy efficient lighting solutions, personal care and home appliances, as well as
consumer electronics. News from Philips is located at </I><U><I>www.philips.com/newscenter</I></U><I>.</I>
</DIV>

<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>Forward-looking statements</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>This release may contain certain forward-looking statements with respect to the financial
condition, results of operations and business of Philips and certain of the plans and objectives of
Philips with respect to these items. By their nature, forward-looking statements involve risk and
uncertainty because they relate to events and depend on circumstances that will occur in the future
and there are many factors that could cause actual results and developments to differ materially
form those expressed or implied by these forward-looking statements. Any forward-looking
statements in this announcement are based upon information known to Philips on the date of this
announcement. Philips undertakes no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or otherwise.</I>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Philips agrees to sell Set-Top Boxes and Connectivity Solutions businesses to Pace Micro Technology
of the UK
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Wednesday, December&nbsp;19, 2007

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Amsterdam, The Netherlands </B>&#151; Royal Philips Electronics (AEX: PHI, NYSE: PHG) today announced it has
reached an agreement in principle to sell its Set-Top Boxes (STB)&nbsp;and Connectivity Solutions (CS)
businesses, currently part of its Home Networks business unit within the Consumer Electronics
division, to U.K.-based technology provider Pace Micro Technology (FTSE: PIC). Philips agreed in
principle to divest the STB and CS businesses to Pace in exchange for 70&nbsp;million Pace shares. The
proposed transaction is subject to approvals from Pace shareholders, the relevant regulatory
authorities and Philips&#146; workers council. After its successful completion, Philips will become a
23% shareholder in the combined business, representing a market value of around EUR 90&nbsp;million
calculated with the closing price of Pace shares on December&nbsp;18. The transaction is expected to
close in the first quarter of 2008.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The outcome of the transaction will result in a combination of strengths of two leading players in
the industry, creating one of the largest set-top-box players in the world at a time when the shift
from analog to digital TV is rapidly increasing. Commenting on the sale, Philippe Alcaras, Business
Unit leader Philips Home Networks said: &#147;We feel that the rapidly changing dynamics of the markets
in which the STB and CS businesses operate will inevitably culminate in further industry
consolidation. By striking a deal with Pace now, we gain the first-mover advantage and it shows
Philips&#146; determination to secure a leading role for our businesses, and make them even more
relevant to our customers and technology partners.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Generating estimated revenues of EUR 425&nbsp;million in 2007, the STB and CS businesses together employ
approximately 335 people, predominantly based in France, who would transfer to Pace as part of the
transaction. The remainder of Home Networks, Home Communications, which includes Internet Telephony
and Home Telephony (DECT), will become part of the Peripherals &#038; Accessories unit within Philips&#146;
Consumer Lifestyle sector.
</DIV>

<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>For further information, please contact:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Joon Knapen<BR>
Philips Corporate Communications<BR>
Tel: &#043;31 20 59 77477<BR>
Email: <u> joon.knapen@philips.com</u>

</DIV>

<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>About Royal Philips Electronics</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in
healthcare, lighting and consumer lifestyle, delivering products, services and solutions through
the brand promise of &#147;sense and simplicity&#148;. Headquartered in the Netherlands, Philips employs
approximately 128,100 employees in more than 60 countries worldwide. With sales of EUR 27&nbsp;billion
in 2006, the company is a market leader in medical diagnostic imaging and patient monitoring
systems, energy efficient</I>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>lighting solutions, personal care and home appliances, as well as consumer electronics. News from
Philips is located at </I><U><I>www.philips.com/newscenter</I></U><I>.</I>
</DIV>

<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>About Pace Micro Technology</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Pace Micro Technology (FTSE: PIC) is a leading technology developer for the global pay-TV industry.
Pace&#146;s main focus is on creating intelligent and innovative products and services that benefit our
customers and fuel the development of digital TV. Over the last 25&nbsp;years, Pace has developed one of
the world&#146;s most experienced specialist engineering teams and is now the partner of choice for
leading pay-TV operators across the globe. Pace&#146;s international headquarters are in Saltaire, West
Yorkshire, U.K., with further offices in the U.S., France, India and Hong Kong. News from Pace is
located at: </I><U><I>www.pacemicro.com/corporate/newsroom</I></U><I>.</I>
</DIV>

<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>Forward-looking statements</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>This release may contain certain forward-looking statements with respect to the financial
condition, results of operations and business of Philips and certain of the plans and objectives of
Philips with respect to these items. By their nature, forward-looking statements involve risk and
uncertainty because they relate to events and depend on circumstances that will occur in the future
and there are many factors that could cause actual results and developments to differ materially
form those expressed or implied by these forward-looking statements. Any forward-looking
statements in this announcement are based upon information known to Philips on the date of this
announcement. Philips undertakes no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or otherwise.</I>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Philips plans to repurchase an additional EUR 5&nbsp;billion worth of shares
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Wednesday, December&nbsp;19, 2007

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Amsterdam, The Netherlands </B>&#151; Royal Philips Electronics (NYSE:PHG, AEX:PHI) today announced that it
plans to repurchase EUR 5&nbsp;billion worth of common Philips shares within the next two years. Shares
repurchased under this new program will be subsequently cancelled. The announcement of this new
share repurchase program follows the adoption by the Dutch parliament last night of an amendment in
Dutch tax legislation, effective January 1st 2008, that increases the amount that companies may
spend repurchasing shares free of withholding tax.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;This new program has been enabled by a more investor-friendly tax regime in the Netherlands that
Philips has been advocating for a while and which will increase the tax efficient share repurchase
capacity of companies within its scope. I am very pleased that as a result we are now able to take
this additional important step in our capital re-allocation process,&#148; Philips President and Chief
Executive Officer Gerard Kleisterlee said. &#147;With this share repurchase program now in place,
combined with the EUR 5.2&nbsp;billion worth of shares already repurchased since 2005 and the EUR 6.5
billion of acquisitions which we have completed or announced in the same period, Philips is well
under way to achieve its goal of an efficient balance sheet before the end of 2009.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Philips&#146; capital reallocation program aims to fuel growth at key businesses through value-creating
acquisitions, while maintaining a good balance with capital redistribution to shareholders. This
process has successfully positioned Philips as a focused, market-driven and people-centric company
active in the areas of Healthcare, Lighting and Consumer Lifestyle.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">As a consequence of this new share repurchase program, Philips will terminate as of today its
second trading line through which EUR 820&nbsp;million worth of shares were purchased out of an
initially planned amount of EUR 1.63&nbsp;billion.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Philips intends to begin this repurchase program as of January 2nd 2008 and will enter into
subsequent discretionary management agreements with one or more banks to repurchase Philips shares
within the limits of relevant laws and regulations (in particular EC Regulation&nbsp;2273/2003) and
Philips&#146; articles of association. All transactions under this program will be published on the
Philips&#146; website (<u>www.philips.com/investor</u>) on a weekly basis.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The appropriate authorizations to complete the program will be proposed to the 2008 Annual General
Meeting of shareholders.
</DIV>

<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>For further information, please contact:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Arent Jan Hesselink<BR>
Philips Corporate Communications<BR>
Tel: &#043;31 20 59 77415<BR>
Email: <u>arentjan.hesselink@philips.com</u>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>About Royal Philips Electronics</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in
healthcare, lighting and consumer lifestyle, delivering products, services and solutions through
the brand promise of &#147;sense and simplicity&#148;. Headquartered in the Netherlands, Philips employs
approximately 128,100 employees in more than 60 countries worldwide. With sales of EUR 27&nbsp;billion
in 2006, the company is a market leader in medical diagnostic imaging and patient monitoring
systems, energy efficient lighting solutions, personal care and home appliances, as well as
consumer electronics. News from Philips is located at </I><U><I>www.philips.com/newscenter</I></U><I>.</I>
</DIV>

<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>Forward-looking statements</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>This release may contain certain forward-looking statements with respect to the financial
condition, results of operations and business of Philips and certain of the plans and objectives of
Philips with respect to these items. By their nature, forward-looking statements involve risk and
uncertainty because they relate to events and depend on circumstances that will occur in the future
and there are many factors that could cause actual results and developments to differ materially
form those expressed or implied by these forward-looking statements. Any forward-looking
statements in this announcement are based upon information known to Philips on the date of this
announcement. Philips undertakes no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or otherwise.</I>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">U.S. antitrust conditions fulfilled for Philips&#146; acquisition of Genlyte
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Wednesday, December&nbsp;19, 2007

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Amsterdam, the Netherlands </B>&#151; Royal Philips Electronics (NYSE:PHG, AEX:PHI) (&#147;Philips&#148;) today
announced the expiration, as of 11:59&nbsp;p.m. EST on December&nbsp;17, 2007, of the mandatory waiting
period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the &#147;HSR Act&#148;),
applicable to the previously announced tender offer by Philips&#146; indirect wholly owned subsidiary
Golf Merger Sub, Inc. (&#147;Philips Merger Sub&#148;) for all outstanding shares of common stock of The
Genlyte Group Incorporated (&#147;Genlyte,&#148; ) for $95.50 per Genlyte share, without interest and subject
to any applicable withholding of taxes. The expiration of the mandatory waiting period under the
HSR Act is a condition to Philips Merger Sub&#146;s obligation to accept for payment and to pay for the
Genlyte shares tendered into the tender offer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On November&nbsp;30, 2007, Philips Merger Sub commenced the tender offer for the Genlyte shares, which
is being made in accordance with the Agreement and Plan of Merger, dated as of November&nbsp;25, 2007,
by and among Genlyte, Philips Holding USA Inc. and Philips Merger Sub (the &#147;merger agreement&#148;). The
offer and withdrawal rights will expire at 12:00 midnight EST on January&nbsp;2, 2008, unless the offer
is extended in accordance with the merger agreement and the Tender Offer Statement on Schedule&nbsp;TO
(containing the offer to purchase, a letter of transmittal and related materials) relating to the
tender offer that has been filed with the Securities and Exchange Commission (the &#147;SEC&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Investors and stockholders of Genlyte are urged to read the Tender Offer Statement on Schedule&nbsp;TO
because it contains important information, including the various terms of, and conditions to, the
tender offer. Investors and stockholders of Genlyte may obtain these and other documents regarding
the tender offer, the merger and the related transactions filed by Philips and Genlyte for free
from the SEC&#146;s website at <u>www.sec.gov</u>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Georgeson Inc. is the Information Agent for the tender offer and any questions or requests for
assistance or free copies of the offer to purchase and the letter of transmittal may be directed to
it at 199 Water Street, 26th Floor, New York, NY 10004 or by telephone toll-free at (888)&nbsp;679-2871
or at (212)&nbsp;440-9800 (bankers and brokers only). Goldman, Sachs &#038; Co. is the Dealer Manager for the
tender offer and can be reached at 85 Broad Street, New York, NY 10004 or by telephone toll-free at
(800)&nbsp;323-5678 or collect at (212)&nbsp;902-1000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This release is for informational purposes only and is not an offer to purchase or a solicitation
of an offer to purchase Genlyte Shares, nor is it an offer or solicitation of an offer to sell any
securities. The tender offer is made solely by means of the offer to purchase.
</DIV>

<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>For more information, please contact:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Jayson Otke

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Philips Corporate Communications<BR>
Tel: &#043;31 20 5977215<BR>
Email: <B><u>jayson.otke@philips.com</u></B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">David Wolf<BR>
Philips Corporate Communications North America<BR>
Tel: &#043;1 917-455-7857<BR>
Email: <u>david.l.wolf@philips.com</u>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Raymond L. Zaccagnini<BR>
Genlyte Group<BR>
Tel: &#043;1 502 420 9500<BR>
Email: <u>rzaccagnini@genlytegroup.com</u>

</DIV>

<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>About Royal Philips Electronics</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in
healthcare, lighting and consumer lifestyle, delivering products, services and solutions through
the brand promise of &#147;sense and simplicity&#148;. Headquartered in the Netherlands, Philips employs
approximately 128,100 employees in more than 60 countries worldwide. With sales of EUR 27&nbsp;billion
in 2006, the company is a market leader in medical diagnostic imaging and patient monitoring
systems, energy efficient lighting solutions, personal care and home appliances, as well as
consumer electronics. News from Philips is located at </I><U><I>www.philips.com/newscenter</I></U><I>.</I>
</DIV>

<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>Forward-looking statements</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>This release may contain certain forward-looking statements with respect to the financial
condition, results of operations and business of Philips and certain of the plans and objectives of
Philips with respect to these items, including without limitation completion of the tender offer
and merger and any expected benefits of the merger. Completion of the tender offer and merger are
subject to conditions, including satisfaction of a minimum tender condition and the need for
regulatory approvals, and there can be no assurance that those conditions can be satisfied or that
the transactions described in this press release will completed. By their nature, forward-looking
statements involve risk and uncertainty because they relate to events and depend on circumstances
that will occur in the future and there are many factors that could cause actual results and
developments to differ materially from those expressed or implied by these forward-looking
statements. Any forward-looking statements in this announcement are based upon information known
to Philips on the date of this announcement. Philips undertakes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new information, future events or
otherwise.</I>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Philips to make public offer for all shares of US-based Respironics; a major step forward for
Philips Healthcare
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Friday, December&nbsp;21, 2007

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Philips and Respironics agree to all-cash offer of USD 66 per share; total transaction
price of approximately EUR 3.6&nbsp;billion</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Acquisition significantly strengthens Philips Healthcare, will provide a strategic
platform for further growth and leverages the acquisitions of Lifeline and Raytel</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Acquisition will make Philips a leader in the global Home Healthcare space and in the
fast-growing field of obstructive sleep apnea management and home respiratory care</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Philips&#146; &#145;in-hospital&#146; position also strengthened through acquisition given
Respironics&#146; strong non-invasive ventilation and respiratory monitoring products for
hospitals and clinics</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Respironics Board of Directors recommends offer to shareholders</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Amsterdam, the Netherlands and Murrysville, Pennsylvania, USA </B>&#151; Royal Philips Electronics (AEX:
PHI, NYSE: PHG) (&#147;Philips&#148;) and Respironics, Inc (Nasdaq: RESP) today announced a definitive merger
agreement pursuant to which Philips will commence a tender offer to acquire all of the outstanding
shares of Respironics for USD 66 per share, or a total purchase price of approximately EUR 3.6
billion (USD 5.1&nbsp;billion) to be paid in cash upon completion. This transaction will firmly place
Philips as a global leader in the fast-growing home healthcare market by adding new product
categories in obstructive sleep apnea and home respiratory care to its existing businesses in this
field. In addition, this acquisition will be highly complementary to Philips&#146; patient monitoring
businesses in the hospital setting. The board of directors of Respironics has unanimously approved
the transaction and recommends the offer to their shareholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Respironics, based in Murrysville, Pennsylvania, USA, is the leading provider of innovative
solutions for the global sleep therapy and respiratory markets. The fast-growing company develops,
manufactures, distributes and markets innovative products in the field of respiratory medical
technology, which are used in both home settings as well as in hospitals and clinics. Respironics
has approximately 5,300 employees worldwide.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;Respironics is an excellent strategic fit and will significantly drive our growth in healthcare
both in the hospital and in the home,&#148; said Gerard Kleisterlee, President and Chief Executive
Officer of Royal Philips Electronics. &#147;The acquisition of Respironics is another major milestone
towards the completion of our objective to build market leadership positions in high-growth,
high-margin businesses across the three market sectors of healthcare, lighting and consumer
lifestyle. It is also another significant step in our continuing capital re-allocation process.
With about EUR 10&nbsp;billion worth of closed or announced acquisitions since 2005 and EUR 10.2&nbsp;billion
of realized or announced share repurchase programs during the same period, we are well on track to
deliver an efficient balance sheet before the end of 2009.&#148;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Almost three-quarters of Respironics&#146; sales are achieved in the company&#146;s Sleep and Home
Respiratory business which consists of diagnostic and therapeutic devices for sleep disordered
breathing and chronic respiratory diseases. Respironics is a global leader in the treatment of
Obstructive Sleep Apnea (OSA), a condition characterized by the repeated cessation of breathing
during sleep. It is estimated that in the United States alone there are 18 &#151; 20&nbsp;million sufferers
of moderate or severe OSA of which only 15 &#151; 20% have been diagnosed. Research in recent years has
shown a link between OSA, heart disease, stroke and diabetes. Additionally, the company has a
leading position in noninvasive ventilation and has recently introduced new home oxygen
technologies to serve the needs of respiratory impaired patients in the home. The remainder of the
Company&#146;s business is focused on the hospital channel and includes noninvasive and invasive
ventilation, respiratory monitoring, neonatal products and respiratory drug delivery technologies
for the treatment of respiratory diseases.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Growth in the USD 5&nbsp;billion plus global respiratory markets is expected to be at least 10% per
annum going forward and the market for global sleep apnea management in particular is expected to
show a mid-teen percentage growth rate annually in the coming years, as rising awareness of this
potentially life-threatening condition leads to increasing diagnosis and treatment of OSA. Growth
in the global sleep and respiratory markets is expected to be particularly significant in Asia and
Europe, where Philips&#146; strong brand combined with the sales and distribution channels of both
organizations will further accelerate adoption of Respironics&#146; innovative portfolio.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;A core part of Philips&#146; healthcare strategy is to take a leading position in the high-growth
sector of home healthcare,&#148; Steve Rusckowski, Chief Executive Officer of Philips Healthcare and
member of the Board of Management of Royal Philips, said. &#147;This acquisition, with its significant
strategic and financial benefits to Philips Healthcare, is another important step in carrying out
this strategy.&#148; Upon completion of this acquisition, Respironics will become the centerpiece of
Home Healthcare Solutions, which will form part of Philips Healthcare as of January&nbsp;1, 2008.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;The transaction we are announcing today will deliver superior and certain value to Respironics&#146;
shareholders,&#148; said John L. Miclot, President and Chief Executive Officer of Respironics. &#147;The
combination of Respironics and Philips will allow us to continue to provide exceptional products
and services to our customers and allow Respironics to expand its leadership in the global sleep
and respiratory markets. Philips is the right partner to create additional growth opportunities for
our company, and we believe that our company will benefit significantly by being part of a larger,
growing and dynamic organization. We look forward to working with Philips to ensure an effective
and seamless transition.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Philips has made a number of successful acquisitions in the area of Home Healthcare so far. Last
year Philips announced the acquisition of Lifeline Systems, and Health Watch and Raytel Cardiac
Services were added this year. Philips Home Healthcare Solutions already offers a range of
solutions that enable the treatment and monitoring of patients in the surroundings of their
personal living space rather than in a hospital
environment. Today, Philips Home Healthcare Solutions supports almost one million at-risk seniors,
either in their own homes or in senior living facilities throughout the U.S. and Canada.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Cost synergies expected from this transaction will be primarily based on supply chain optimization
and savings in general and administrative expenses including IT related synergies to be achieved by
leveraging Respironics&#146; strong IT infrastructure. Respironics&#146; respiratory management portfolio is
synergistic with Philips&#146; current offerings in patient monitoring, from pre-hospital admission to
long-term disease management in the home. The combined businesses will profit from cross-selling
opportunities leveraging Philips&#146; existing strengths in both the hospital and the home. The
transaction will be immediately accretive to revenue growth as well as EBITA margin to Philips and
Philips Healthcare.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Over a twelve month period ending in September&nbsp;2007, Respironics reported sales of approximately
USD 1.2&nbsp;billion with an EBITDA margin of 19%. In its last five fiscal years Respironics has seen
revenues grow at a compound annual growth rate of 19% whilst the EBITA margin grew at a compound
annual growth rate of 20% over this period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This transaction is structured as an all-cash tender offer by Philips for all of the issued and
outstanding shares of Respironics, to be followed by a merger in which each remaining un-tendered
share of Respironics will be converted into the USD 66 per share price paid in the tender offer.
The tender offer is expected to commence by January&nbsp;8, 2008 and is not subject to any financing
contingency. The acquisition will be effected pursuant to a merger agreement and is subject to the
terms and conditions of that agreement. These include the tender of a majority of the outstanding
Respironics shares, as well as customary U.S. and EU regulatory clearances. The transaction is
expected to close in the first quarter of 2008 upon which Respironics will become the headquarters
for Philips Home Healthcare Solutions group within Philips Healthcare.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">At 10.00 AM CET today, financial analysts are invited to join a telephone conference with Gerard
Kleisterlee, Philips&#146; President and CEO, Pierre-Jean Sivignon, Chief Financial Officer of Philips
and Steve Rusckowski, Chief Executive Officer of Philips Healthcare. A live webcast of this
conference call and a presentation with regard to this transaction will be made available on
Philips&#146; Investor Relations website at: <u>http://www.philips.com/about/investor/index.page</u>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">At 11.30 AM CET today, journalists are invited to join a telephone briefing with Mr Kleisterlee, Mr
Sivignon and Mr.&nbsp;Rusckowski. A live webcast of this briefing will be made available on Philips&#146;
News Center website at: <u>http://www.newscenter.philips.com/about/news/index.page</u>
</DIV>

<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>Background information</B>
</DIV>


<DIV align="left" style="font-size: 12pt; margin-top: 6pt"><B>&#043;  <u>Click here for all background information, including the media backgrounders, presentation,
webcasts, biographies and images.</u></B>
</DIV>

<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>For further information, please contact:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Arent Jan Hesselink

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Philips Corporate Communications<BR>
Tel: &#043;31 20 59 77415<BR>
Email: <u>arentjan.hesselink@philips.com</u>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Andre Manning<BR>
Philips Healthcare Communications<BR>
Tel: &#043;1 646 508 4545<BR>
Email: <u>andre.manning@philips.com</u>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dan Bevevino<BR>
Vice President &#038; CFO, Respironics<BR>
Tel: &#043;1 724 387 5235

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Maryellen Bizzack<BR>
Director, Marketing &#038; Communications, Respironics<BR>
Tel: &#043;1 724 387 5006

</DIV>

<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>About Royal Philips Electronics</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in
healthcare, lighting and consumer lifestyle, delivering people-centric, innovative products,
services and solutions through the brand promise of &#147;sense and simplicity&#148;. Headquartered in the
Netherlands, Philips employs approximately 128,100 employees in more than 60 countries worldwide.
With sales of EUR 27&nbsp;billion in 2006, the company is a market leader in medical diagnostic imaging
and patient monitoring systems, energy efficient lighting solutions, as well as lifestyle solutions
for personal wellbeing. News from Philips is located at </I><U><I>www.philips.com/newscenter</I></U><I>.</I>
</DIV>

<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>About Respironics</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Respironics is a leading developer, manufacturer and distributor of innovative products and
programs that serve the global sleep and respiratory markets. Focusing on emerging market needs,
the Company is committed to providing valued solutions to help improve outcomes for patients,
clinicians and healthcare providers. Respironics markets its products in 141 countries and employs
over 5,300 associates worldwide. Further information can be found on the Company&#146;s Web site:</I>
<U><I>www.respironics.com</I></U><I>.</I>
</DIV>

<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>Forward-looking statements</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>This release may contain certain forward-looking statements with respect to the financial
condition, results of operations and business of Philips and certain of the plans and objectives of
Philips with respect to these items. By their nature, forward-looking statements involve risk and
uncertainty because they relate to events and depend on circumstances that will occur in the future
and there are many factors that
could cause actual results and developments to differ materially from those expressed or implied by
these forward-looking statements.</I>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>Additional Information</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>The tender offer described in this press release has not yet commenced, and this press release is
neither an offer to purchase nor a solicitation of an offer to sell Respironics&#146;s common stock.
Investors and security holders are urged to read both the tender offer statement and the
solicitation/recommendation statement regarding the tender offer described in this press release
when they become available because they will contain important information. The tender offer
statement will be filed by Moonlight Merger Sub, Inc., a fully-owned subsidiary of Philips Holding
USA Inc., which is a fully-owned subsidiary of Royal Philips Electronics, with the Securities and
Exchange commission (&#147;SEC&#148;) and the solicitation/recommendation statement will be filed by
Respironics with the SEC. Investors and security holders may obtain a free copy of these statements
(when available) and other documents filed by Philips or Respironics with the SEC at the website
maintained by the SEC at </I><U><I>www.sec.gov</I></U><I>. The tender offer statement and related materials,
solicitation/recommendation statement, and such other documents may be obtained for free by
directing such requests to Investor Relations of Respironics at 1010 Murry Ridge Lane, Murrysville,
PA 15668.</I>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
